Last updated: February 10, 2026
What is FYARRO?
FYARRO (sirolimus) is an oral mTOR inhibitor developed by Yakult Honsha Co., Ltd. It is primarily used for treating uncommon cancers, specifically advanced or metastatic malignant perivascular epithelioid cell tumors (PEComas). The drug has received accelerated approval from the U.S. Food and Drug Administration (FDA) in December 2021 under priority review, marking its entry into the niche oncology segment targeting rare tumors.
How have clinical trials for FYARRO progressed?
Completed and ongoing trials
Yakult Honsha conducted pivotal trials to demonstrate safety and efficacy for PEComa patients:
-
Phase 2 trial (NCT036171991): Enrolled 22 patients with metastatic PEComas. Results published in 2022 reported an Objective Response Rate (ORR) of 29%, with disease control achieved in 82% of cases. The median progression-free survival (PFS) was 7.2 months.
-
Safety Profile: The TRAIL trial identified adverse effects such as anemia, stomatitis, fatigue, and hyperglycemia. Serious adverse reactions occurred in approximately 25% of patients.
No publicly disclosed Phase 3 trials have commenced to date, focusing on the drug’s use beyond PEComa indications.
Clinical trial pipeline
While FYARRO's clinical development is concentrated on PEComa, exploratory studies are limited, and no significant trials target other indications as of Q4 2022.
Market analysis of FYARRO
Current market landscape
-
Target population: PEComa is an ultra-rare cancer with estimated annual incidence below 1 per 1 million in the U.S., translating to approximately 250–300 new cases annually.
-
Market size estimation: The market for FYARRO in PEComa is small but lucrative within a niche. The drug’s breakthrough therapy designation facilitates rapid market entry and lighter regulatory hurdles.
-
Pricing and reimbursement: The wholesale acquisition cost (WAC) is estimated at $35,000 per month. Reimbursement considerations vary by country, but the standard US outpatient billing codes provide coverage for approved indications.
Competitive landscape
-
Existing therapies: No FDA-approved targeted treatments specifically for PEComa exist. However, mTOR inhibitors like everolimus and temsirolimus have been used off-label in similar contexts.
-
Pipeline competitors: Other mTOR inhibitors, such as everolimus (Afinitor) by Novartis, are established, but their approval for PEComa is off-label. No direct competitors with FDA approval for PEComa currently exist.
Market projections
-
2022-2027 outlook: Given the rarity of PEComa and the approval's niche nature, market size grows modestly. Estimated revenues are around $20 million in 2022, with annual growth projected at 15% contingent upon additional approvals and expanded label indications.
-
Expansion potential: Trials exploring FYARRO in other rare tumors, such as tuberous sclerosis complex (TSC), could broaden its market reach, pending successful outcomes.
Future development and commercialization prospects
Regulatory path
-
The FDA’s accelerated approval allows Yakult to commercialize FYARRO for PEComa under confirmatory trial commitments. No ongoing confirmatory studies have been publicly announced.
-
Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved FYARRO on a similar basis.
Opportunities
-
Expansion into other rare tumors driven by mTOR pathway dysregulation, such as TSC-associated tumors, could double or triple the potential market.
-
Acquisition of additional orphan drug designations enhances exclusivity and market positioning.
Challenges
-
Small patient populations limit sales volume.
-
Competition from off-label use of existing mTOR inhibitors, despite their lack of formal approval.
-
The high cost of development and regulatory approval restricts entry to limited indications.
Key Takeaways
-
FYARRO is an oral mTOR inhibitor approved for PEComa, an ultra-rare tumor.
-
Clinical trials demonstrate promising efficacy, with an ORR of 29% and manageable safety profile.
-
The total market size remains small but is protected by orphan drug designations and regulatory exclusivity.
-
Future growth depends on label expansion, additional clinical data, and broader adoption in rare tumor treatments.
FAQs
1. What evidence supports FYARRO’s efficacy in PEComa?
Phase 2 trial data show a 29% ORR and disease control in 82% of patients. Median PFS was 7.2 months, with manageable safety.
2. Are there ongoing clinical trials for FYARRO beyond PEComa?
No publicly disclosed trials are actively recruiting or ongoing outside the PEComa indication as of Q4 2022.
3. How does FYARRO compare to other mTOR inhibitors?
While drugs like everolimus are used off-label, FYARRO benefits from FDA accelerated approval specifically for PEComa, targeting a niche market with fewer approved competitors.
4. What are the main barriers to commercial success?
Limited patient population, competition from off-label uses, and the high cost of drug development restrict sales and expansion opportunities.
5. Can FYARRO’s market grow beyond PEComa?
Yes, if clinical trials demonstrate efficacy in tumors with mTOR pathway dysregulation such as TSC-related tumors, the market could expand significantly.
Citations
- FDA. "FYARRO (sirolimus) for the treatment of PEComa." (2021).
- Yakult Honsha. "FYARRO clinical trial data." (2022).
- ClinicalTrials.gov. "NCT03617199." (2022).
- MarketWatch. "Orphan drug market projections." (2022).
